Your browser doesn't support javascript.
loading
Clinical testing of transcriptome-wide expression profiles in high-risk localized and metastatic prostate cancer starting androgen deprivation therapy: an ancillary study of the STAMPEDE abiraterone Phase 3 trial.
Parry, Marina A; Grist, Emily; Mendes, Larissa; Dutey-Magni, Peter; Sachdeva, Ashwin; Brawley, Christopher; Murphy, Laura; Proudfoot, James; Lall, Sharanpreet; Liu, Yang; Friedrich, Stefanie; Ismail, Mazlina; Hoyle, Alex; Ali, Adnan; Haran, Aine; Wingate, Anna; Zakka, Leila; Wetterskog, Daniel; Amos, Claire L; Atako, Nafisah B; Wang, Victoria; Rush, Hannah L; Jones, Robert J; Leung, Hing; Cross, William R; Gillessen, Silke; Parker, Chris C; Chowdhury, Simon; Lotan, Tamara; Marafioti, Teresa; Urbanucci, Alfonso; Schaeffer, Edward M; Spratt, Daniel E; Waugh, David; Powles, Thomas; Berney, Daniel M; Sydes, Matthew R; Parmar, Mahesh K B; Hamid, Anis A; Feng, Felix Y; Sweeney, Christopher J; Davicioni, Elai; Clarke, Noel W; James, Nicholas D; Brown, Louise C; Attard, Gerhardt.
Afiliação
  • Parry MA; Cancer Institute, University College London; London, UK.
  • Grist E; Cancer Institute, University College London; London, UK.
  • Mendes L; Cancer Institute, University College London; London, UK.
  • Dutey-Magni P; MRC Clinical Trials Unit at University College London, Institute of Clinical Trials and Methodology, University College London; London, UK.
  • Sachdeva A; Genito-Urinary Cancer Research Group, Division of Cancer Sciences, Manchester Cancer Research Centre, The University of Manchester; Manchester, UK.
  • Brawley C; MRC Clinical Trials Unit at University College London, Institute of Clinical Trials and Methodology, University College London; London, UK.
  • Murphy L; MRC Clinical Trials Unit at University College London, Institute of Clinical Trials and Methodology, University College London; London, UK.
  • Proudfoot J; Veracyte, Inc; San Diego, USA.
  • Lall S; Cancer Institute, University College London; London, UK.
  • Liu Y; Veracyte, Inc; San Diego, USA.
  • Friedrich S; Cancer Institute, University College London; London, UK.
  • Ismail M; Cancer Institute, University College London; London, UK.
  • Hoyle A; Genito-Urinary Cancer Research Group, Division of Cancer Sciences, Manchester Cancer Research Centre, The University of Manchester; Manchester, UK.
  • Ali A; Department of Surgery, The Christie and Salford Royal Hospitals; Manchester, UK.
  • Haran A; Genito-Urinary Cancer Research Group, Division of Cancer Sciences, Manchester Cancer Research Centre, The University of Manchester; Manchester, UK.
  • Wingate A; Genito-Urinary Cancer Research Group, Division of Cancer Sciences, Manchester Cancer Research Centre, The University of Manchester; Manchester, UK.
  • Zakka L; Department of Surgery, The Christie and Salford Royal Hospitals; Manchester, UK.
  • Wetterskog D; Cancer Institute, University College London; London, UK.
  • Amos CL; Cancer Institute, University College London; London, UK.
  • Atako NB; Cancer Institute, University College London; London, UK.
  • Wang V; MRC Clinical Trials Unit at University College London, Institute of Clinical Trials and Methodology, University College London; London, UK.
  • Rush HL; MRC Clinical Trials Unit at University College London, Institute of Clinical Trials and Methodology, University College London; London, UK.
  • Jones RJ; Department of Data Science, Dana-Farber Cancer Institute; Boston, USA.
  • Leung H; MRC Clinical Trials Unit at University College London, Institute of Clinical Trials and Methodology, University College London; London, UK.
  • Cross WR; University of Glasgow, Beatson West of Scotland Cancer Centre; Glasgow, UK.
  • Gillessen S; University of Glasgow, Beatson West of Scotland Cancer Centre; Glasgow, UK.
  • Parker CC; St James's University Hospital; Leeds, UK.
  • Chowdhury S; Istituto Oncologico della Svizzera Italiana, EOC; Bellinzona, Switzerland.
  • Lotan T; Royal Marsden NHS Foundation Trust and Institute of Cancer Research; London, UK.
  • Marafioti T; Guy's and St Thomas' NHS Foundation Trust; London, UK.
  • Schaeffer EM; Johns Hopkins University School of Medicine; Baltimore, USA.
  • Spratt DE; Cancer Institute, University College London; London, UK.
  • Waugh D; Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital; Oslo, Norway.
  • Powles T; Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center, Tampere University Hospital; Tampere, Finland.
  • Berney DM; Department of Urology, Northwestern University Feinberg School of Medicine; Chicago, USA.
  • Sydes MR; Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center; Cleveland, USA.
  • Parmar MKB; Queensland University of Technology; Brisbane, Australia.
  • Hamid AA; Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London; London, UK.
  • Feng FY; Barts Cancer Institute, Queen Mary University of London; London, UK.
  • Sweeney CJ; MRC Clinical Trials Unit at University College London, Institute of Clinical Trials and Methodology, University College London; London, UK.
  • Davicioni E; MRC Clinical Trials Unit at University College London, Institute of Clinical Trials and Methodology, University College London; London, UK.
  • Clarke NW; Department of Medical Oncology, Dana-Farber Cancer Institute; Boston, USA.
  • James ND; University of California San Francisco; San Francisco, USA.
  • Brown LC; Department of Medical Oncology, Dana-Farber Cancer Institute; Boston, USA.
  • Attard G; Veracyte, Inc; San Diego, USA.
Res Sq ; 2023 Feb 08.
Article em En | MEDLINE | ID: mdl-36798177
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article